{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T11:04:00Z","timestamp":1793271840248,"version":"4.5.0"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2025,4,17]],"date-time":"2025-04-17T00:00:00Z","timestamp":1744848000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,4,17]],"date-time":"2025-04-17T00:00:00Z","timestamp":1744848000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100009367","name":"Mansoura University","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100009367","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Naunyn-Schmiedeberg's Arch Pharmacol"],"published-print":{"date-parts":[[2025,10]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:p>Insomnia is a typical sleep disorder in which an individual finds it difficult to fall asleep and stay asleep resulting in poor daytime functioning and decreased health and quality of life. The orexin system, which regulates wakefulness and arousal, is often overactive in individuals with insomnia, disrupting normal sleep patterns. Lemborexant, a dual orexin receptor antagonist, works through the inhibition of the orexin system, thus facilitating increased sleep onset and maintenance of sleep. This systematic review and meta-analysis seek to determine the effectiveness and safety of lemborexant in the treatment of insomnia. A comprehensive search was conducted on PubMed, Scopus, Web of Science, and Cochrane Library, from inception to September 2024. Four randomized controlled trials (RCTs) assessing the efficacy and safety of lemborexant for patients with confirmed DSM-5 diagnosis of insomnia as compared to placebo were included. By adopting a random-effect inverse variance model, RevMan was used to pool dichotomous and continuous data. We employed the ROB2 methodology to evaluate the quality of the evidence, so ensuring the reliability of the findings obtained throughout these investigations. Four studies with a total of 1976 patients were included. Lemborexant was superior to placebo in decreasing sleep onset latency and wake after sleep onset: (MD\u2009=\u2009\u2009\u2212\u20099.23\u00a0min, <jats:italic>P<\/jats:italic>\u2009=\u20090.02 and MD\u2009=\u2009\u2009\u2212\u200919.9\u00a0min, <jats:italic>P<\/jats:italic>\u2009&lt;\u20090.0001) with 5\u00a0mg and (MD\u2009=\u2009\u2009\u2212\u200912.56\u00a0min, <jats:italic>P<\/jats:italic>\u2009=\u20090.004) and (MD\u2009=\u2009\u2009\u2212\u200922.24\u00a0min, <jats:italic>P<\/jats:italic>\u2009&lt;\u20090.0001) with 10\u00a0mg, respectively. In addition, sleep efficiency was statistically significantly higher in the lemborexant group (MD\u2009=\u20096.08%, <jats:italic>P<\/jats:italic>\u2009&lt;\u20090.0001) and (MD\u2009=\u20097.46%, <jats:italic>P<\/jats:italic>\u2009&lt;\u20090.0001) with 5\u00a0mg and 10\u00a0mg, respectively. Regarding safety analysis, Treatment emerged adverse events (TEAEs) and somnolence were statistically significantly higher in the lemborexant group (RR\u2009=\u20091.94, <jats:italic>P<\/jats:italic>\u2009&lt;\u20090.0001) and (RR\u2009=\u20094.95, <jats:italic>P<\/jats:italic>\u2009&lt;\u20090.0001), respectively. In accordance with this systematic review and meta-analysis, lemborexant is an effective pharmacotherapy for the treatment of insomnia as it improves sleep onset latency, wake after sleep onset, and sleep efficiency. Both formulations of 5-mg and 10-mg doses were well tolerated with no significant difference in their effect; however, somnolence was more common relative to placebo. Lemborexant appears to fill a therapeutic gap in the treatment of insomnia but should be used with caution and smaller dose (5\u00a0mg) in those who are at risk of developing an excessive daytime somnolence state.<\/jats:p>","DOI":"10.1007\/s00210-025-04072-4","type":"journal-article","created":{"date-parts":[[2025,4,17]],"date-time":"2025-04-17T01:13:51Z","timestamp":1744852431000},"page":"12911-12926","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Efficacy and safety of lemborexant vs placebo in treating adults with insomnia disorder: a systematic review and meta-analysis of 1976 patients"],"prefix":"10.1007","volume":"398","author":[{"given":"Mohamed A.","family":"Alsaied","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdelrahman M.","family":"Elettreby","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ibrahim","family":"Serag","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jaisingh","family":"Rajput","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nourhan Abas","family":"Zabady","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huansheng","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmed A.","family":"Abo Elnaga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,4,17]]},"reference":[{"issue":"1","key":"4072_CR1","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1007\/s40614-021-00284-0","volume":"45","author":"O Aydin","year":"2021","unstructured":"Aydin O, Yassikaya MY (2021) Validity and reliability analysis of the PlotDigitizer software program for data extraction from single-case graphs. Perspect Behav Sci 45(1):239\u2013257. https:\/\/doi.org\/10.1007\/s40614-021-00284-0","journal-title":"Perspect Behav Sci"},{"key":"4072_CR2","doi-asserted-by":"crossref","unstructured":"American Psychiatric Association (2013) Diagnostic and statistical manual of mental disorders, Fifth Edition. American Psychiatric Association","DOI":"10.1176\/appi.books.9780890425596"},{"key":"4072_CR3","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1097\/01.yco.0000165594.60434.84","volume":"18","author":"H Ashton","year":"2005","unstructured":"Ashton H (2005) The diagnosis and management of benzodiazepine dependence. Curr Opin Psychiatry 18:249\u2013255. https:\/\/doi.org\/10.1097\/01.yco.0000165594.60434.84","journal-title":"Curr Opin Psychiatry"},{"key":"4072_CR4","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1124\/jpet.117.241422","volume":"362","author":"CT Beuckmann","year":"2017","unstructured":"Beuckmann CT, Suzuki M, Ueno T et al (2017) In vitro and in silico characterization of lemborexant (E2006), a novel dual orexin receptor antagonist. J Pharmacol Exp Ther 362:287\u2013295. https:\/\/doi.org\/10.1124\/jpet.117.241422","journal-title":"J Pharmacol Exp Ther"},{"key":"4072_CR5","doi-asserted-by":"publisher","first-page":"1335","DOI":"10.1007\/s11606-007-0251-z","volume":"22","author":"N Buscemi","year":"2007","unstructured":"Buscemi N, Vandermeer B, Friesen C et al (2007) The efficacy and safety of drug treatments for chronic insomnia in adults: a meta-analysis of RCTs. J Gen Intern Med 22:1335\u20131350. https:\/\/doi.org\/10.1007\/s11606-007-0251-z","journal-title":"J Gen Intern Med"},{"key":"4072_CR6","doi-asserted-by":"publisher","first-page":"706","DOI":"10.1001\/jama.2013.193","volume":"309","author":"DJ Buysse","year":"2013","unstructured":"Buysse DJ (2013) Insomnia. JAMA 309:706\u2013716. https:\/\/doi.org\/10.1001\/jama.2013.193","journal-title":"JAMA"},{"key":"4072_CR7","unstructured":"Cochrane handbook for systematic reviews of interventions (n.d.). https:\/\/training.cochrane.org\/handbook. Accessed 5 Jul 2024"},{"key":"4072_CR8","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1016\/S0140-6736(22)00878-9","volume":"400","author":"F De Crescenzo","year":"2022","unstructured":"De Crescenzo F, D\u2019Al\u00f2 GL, Ostinelli EG et al (2022) Comparative effects of pharmacological interventions for the acute and long-term management of insomnia disorder in adults: a systematic review and network meta-analysis. The Lancet 400:170\u2013184. https:\/\/doi.org\/10.1016\/S0140-6736(22)00878-9","journal-title":"The Lancet"},{"key":"4072_CR9","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1136\/bmj.315.7109.629","volume":"315","author":"M Egger","year":"1997","unstructured":"Egger M, Smith GD, Schneider M, Minder C (1997) Bias in meta-analysis detected by a simple, graphical test. BMJ 315:629\u2013634. https:\/\/doi.org\/10.1136\/bmj.315.7109.629","journal-title":"BMJ"},{"key":"4072_CR10","unstructured":"EndNote | The Best Citation & Reference Management Tool (n.d.) In: EndNote. https:\/\/endnote.com\/. Accessed 19 Sep 2023"},{"key":"4072_CR11","doi-asserted-by":"publisher","DOI":"10.1002\/9781119536604","volume-title":"Cochrane handbook for systematic reviews of interventions","author":"JPT Higgins","year":"2019","unstructured":"Higgins JPT, Thomas J, Chandler J et al (2019) Cochrane handbook for systematic reviews of interventions, 1st edn. Wiley","edition":"1"},{"key":"4072_CR12","doi-asserted-by":"publisher","first-page":"zsaa123","DOI":"10.1093\/sleep\/zsaa123","volume":"43","author":"M K\u00e4rpp\u00e4","year":"2020","unstructured":"K\u00e4rpp\u00e4 M, Yardley J, Pinner K et al (2020) Long-term efficacy and tolerability of lemborexant compared with placebo in adults with insomnia disorder: results from the phase 3 randomized clinical trial SUNRISE 2. Sleep 43:zsaa123. https:\/\/doi.org\/10.1093\/sleep\/zsaa123","journal-title":"Sleep"},{"key":"4072_CR13","first-page":"229","volume":"51","author":"DA Katz","year":"2002","unstructured":"Katz DA, McHorney CA (2002) The relationship between insomnia and health-related quality of life in patients with chronic illness. J Fam Pract 51:229\u2013235","journal-title":"J Fam Pract"},{"key":"4072_CR14","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1016\/j.jpsychires.2020.05.025","volume":"128","author":"T Kishi","year":"2020","unstructured":"Kishi T, Nomura I, Matsuda Y et al (2020) Lemborexant vs suvorexant for insomnia: a systematic review and network meta-analysis. J Psychiatr Res 128:68\u201374. https:\/\/doi.org\/10.1016\/j.jpsychires.2020.05.025","journal-title":"J Psychiatr Res"},{"key":"4072_CR15","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1016\/j.sleep.2009.01.002","volume":"10","author":"DF Kripke","year":"2009","unstructured":"Kripke DF (2009) Do hypnotics cause death and cancer? The burden of proof. Sleep Med 10:275\u2013276. https:\/\/doi.org\/10.1016\/j.sleep.2009.01.002","journal-title":"Sleep Med"},{"key":"4072_CR16","doi-asserted-by":"publisher","first-page":"zpab011","DOI":"10.1093\/sleepadvances\/zpab011","volume":"2","author":"D Mayleben","year":"2021","unstructured":"Mayleben D, Rosenberg R, Pinner K et al (2021) Assessment of morning sleep propensity with lemborexant in adults with insomnia disorder in a randomized, placebo-controlled crossover study. Sleep Adv 2:zpab011. https:\/\/doi.org\/10.1093\/sleepadvances\/zpab011","journal-title":"Sleep Adv"},{"key":"4072_CR17","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1097\/00005650-199303000-00006","volume":"31","author":"CA McHorney","year":"1993","unstructured":"McHorney CA, Ware JE, Raczek AE (1993) The MOS 36-Item Short-Form Health Survey (SF-36): II. Psychometric and clinical tests of validity in measuring physical and mental health constructs. Med Care 31:247\u2013263. https:\/\/doi.org\/10.1097\/00005650-199303000-00006","journal-title":"Med Care"},{"key":"4072_CR18","doi-asserted-by":"publisher","unstructured":"McHorney CA, Ware JE, Rogers W, et al (1992) The validity and relative precision of MOS short-, and long- form health status scales and Dartmouth COOP charts: results from the medical outcomes study. Medical Care 30:MS253\u2013MS265. https:\/\/doi.org\/10.1097\/00005650-199205001-00025","DOI":"10.1097\/00005650-199205001-00025"},{"key":"4072_CR19","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1016\/j.neures.2017.03.015","volume":"118","author":"M Mieda","year":"2017","unstructured":"Mieda M (2017) The roles of orexins in sleep\/wake regulation. Neurosci Res 118:56\u201365. https:\/\/doi.org\/10.1016\/j.neures.2017.03.015","journal-title":"Neurosci Res"},{"key":"4072_CR20","doi-asserted-by":"publisher","first-page":"1129","DOI":"10.1016\/S0140-6736(11)60750-2","volume":"379","author":"CM Morin","year":"2012","unstructured":"Morin CM, Benca R (2012) Chronic insomnia. Lancet 379:1129\u20131141. https:\/\/doi.org\/10.1016\/S0140-6736(11)60750-2","journal-title":"Lancet"},{"key":"4072_CR21","doi-asserted-by":"publisher","first-page":"1398","DOI":"10.1093\/sleep\/29.11.1398","volume":"29","author":"CM Morin","year":"2006","unstructured":"Morin CM, Bootzin RR, Buysse DJ et al (2006) Psychological and behavioral treatment of insomnia: update of the recent evidence (1998\u20132004). Sleep 29:1398\u20131414. https:\/\/doi.org\/10.1093\/sleep\/29.11.1398","journal-title":"Sleep"},{"key":"4072_CR22","doi-asserted-by":"publisher","first-page":"2005","DOI":"10.1001\/jama.2009.682","volume":"301","author":"CM Morin","year":"2009","unstructured":"Morin CM, Valli\u00e8res A, Guay B et al (2009) Cognitive behavioral therapy, singly and combined with medication, for persistent insomnia: a randomized controlled trial. JAMA 301:2005. https:\/\/doi.org\/10.1001\/jama.2009.682","journal-title":"JAMA"},{"key":"4072_CR23","doi-asserted-by":"publisher","first-page":"1289","DOI":"10.5664\/jcsm.6800","volume":"13","author":"P Murphy","year":"2017","unstructured":"Murphy P, Moline M, Mayleben D et al (2017) Lemborexant, A Dual Orexin Receptor Antagonist (DORA) for the treatment of insomnia disorder: results from a Bayesian, adaptive, randomized, double-blind, placebo-controlled study. J Clin Sleep Med 13:1289\u20131299. https:\/\/doi.org\/10.5664\/jcsm.6800","journal-title":"J Clin Sleep Med"},{"key":"4072_CR24","doi-asserted-by":"publisher","unstructured":"Na HJ, Jeon N, Staatz CE, Han N, Baek IH (2024) Clinical safety and narcolepsy-like symptoms of dual orexin receptor antagonists in patients with insomnia: a systematic review and meta-analysis. Sleep 47(2):zsad293. https:\/\/doi.org\/10.1093\/sleep\/zsad293","DOI":"10.1093\/sleep\/zsad293"},{"key":"4072_CR25","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1186\/s13643-016-0384-4","volume":"5","author":"M Ouzzani","year":"2016","unstructured":"Ouzzani M, Hammady H, Fedorowicz Z, Elmagarmid A (2016) Rayyan\u2014a web and mobile app for systematic reviews. Syst Rev 5:210. https:\/\/doi.org\/10.1186\/s13643-016-0384-4","journal-title":"Syst Rev"},{"key":"4072_CR26","doi-asserted-by":"publisher","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, et al (2021) The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ n71. https:\/\/doi.org\/10.1136\/bmj.n71","DOI":"10.1136\/bmj.n71"},{"key":"4072_CR27","doi-asserted-by":"publisher","first-page":"125","DOI":"10.7326\/M15-2175","volume":"165","author":"A Qaseem","year":"2016","unstructured":"Qaseem A, Kansagara D, Forciea MA et al (2016) Management of chronic insomnia disorder in adults: a clinical practice guideline from the American College of Physicians. Ann Intern Med 165:125\u2013133. https:\/\/doi.org\/10.7326\/M15-2175","journal-title":"Ann Intern Med"},{"key":"4072_CR28","unstructured":"RevMan (n.d.) https:\/\/training.cochrane.org\/online-learning\/core-software\/revman. Accessed 14 Sep 2023"},{"key":"4072_CR29","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1055\/s-0043-1768667","volume":"81","author":"RB Rocha","year":"2023","unstructured":"Rocha RB, Bomtempo FF, Nager GB et al (2023) Dual orexin receptor antagonists for the treatment of insomnia: systematic review and network meta-analysis. Arq Neuropsiquiatr 81:475\u2013483. https:\/\/doi.org\/10.1055\/s-0043-1768667","journal-title":"Arq Neuropsiquiatr"},{"issue":"12","key":"4072_CR30","doi-asserted-by":"publisher","first-page":"e1918254","DOI":"10.1001\/jamanetworkopen.2019.18254","volume":"2","author":"R Rosenberg","year":"2019","unstructured":"Rosenberg R, Murphy P, Zammit G, Mayleben D, Kumar D, Dhadda S, Filippov G, LoPresti A, Moline M (2019) Comparison of lemborexant with placebo and zolpidem tartrate extended release for the treatment of older adults with insomnia disorder: a phase 3 randomized clinical trial. JAMA Netw Open 2(12):e1918254. https:\/\/doi.org\/10.1001\/jamanetworkopen.2019.18254","journal-title":"JAMA Netw Open"},{"key":"4072_CR31","doi-asserted-by":"publisher","first-page":"S7","DOI":"10.5664\/jcsm.26929","volume":"3","author":"T Roth","year":"2007","unstructured":"Roth T (2007) Insomnia: definition, prevalence, etiology, and consequences. J Clin Sleep Med 3:S7-10","journal-title":"J Clin Sleep Med"},{"key":"4072_CR32","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1080\/07317115.2012.731478","volume":"36","author":"B Rybarczyk","year":"2013","unstructured":"Rybarczyk B, Lund HG, Garroway AM, Mack L (2013) Cognitive behavioral therapy for insomnia in older adults: background, evidence, and overview of treatment protocol. Clin Gerontol 36:70\u201393. https:\/\/doi.org\/10.1080\/07317115.2012.731478","journal-title":"Clin Gerontol"},{"key":"4072_CR33","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1176\/appi.ajp.159.1.5","volume":"159","author":"MT Smith","year":"2002","unstructured":"Smith MT, Perlis ML, Park A et al (2002) Comparative meta-analysis of pharmacotherapy and behavior therapy for persistent insomnia. AJP 159:5\u201311. https:\/\/doi.org\/10.1176\/appi.ajp.159.1.5","journal-title":"AJP"},{"key":"4072_CR34","doi-asserted-by":"publisher","first-page":"1046","DOI":"10.1016\/S0895-4356(01)00377-8","volume":"54","author":"JAC Sterne","year":"2001","unstructured":"Sterne JAC, Egger M (2001) Funnel plots for detecting bias in meta-analysis. J Clin Epidemiol 54:1046\u20131055. https:\/\/doi.org\/10.1016\/S0895-4356(01)00377-8","journal-title":"J Clin Epidemiol"},{"key":"4072_CR35","doi-asserted-by":"publisher","unstructured":"Sterne JAC, Savovi\u0107 J, Page MJ et al (2019) RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ l4898. https:\/\/doi.org\/10.1136\/bmj.l4898","DOI":"10.1136\/bmj.l4898"},{"key":"4072_CR36","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1159\/000514960","volume":"45","author":"B Toor","year":"2021","unstructured":"Toor B, Ray LB, Pozzobon A, Fogel SM (2021) Sleep, orexin and cognition. Front Neurol Neurosci 45:38\u201351. https:\/\/doi.org\/10.1159\/000514960","journal-title":"Front Neurol Neurosci"},{"key":"4072_CR37","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1016\/j.sleep.2010.09.003","volume":"12","author":"M Xu","year":"2011","unstructured":"Xu M, B\u00e9langer L, Ivers H et al (2011) Comparison of subjective and objective sleep quality in menopausal and non-menopausal women with insomnia. Sleep Med 12:65\u201369. https:\/\/doi.org\/10.1016\/j.sleep.2010.09.003","journal-title":"Sleep Med"},{"key":"4072_CR38","doi-asserted-by":"publisher","first-page":"4648","DOI":"10.1021\/acs.jmedchem.5b00217","volume":"58","author":"Y Yoshida","year":"2015","unstructured":"Yoshida Y, Naoe Y, Terauchi T et al (2015) Discovery of (1 R,2 S )-2-{[(2,4-dimethylpyrimidin-5-yl)oxy]methyl}-2-(3-fluorophenyl)- N -(5-fluoropyridin-2-yl)cyclopropanecarboxamide (E2006): a potent and efficacious oral orexin receptor antagonist. J Med Chem 58:4648\u20134664. https:\/\/doi.org\/10.1021\/acs.jmedchem.5b00217","journal-title":"J Med Chem"},{"key":"4072_CR39","doi-asserted-by":"publisher","first-page":"101746","DOI":"10.1016\/j.smrv.2023.101746","volume":"68","author":"JL Yue","year":"2023","unstructured":"Yue JL, Chang XW, Zheng JW, Shi L, Xiang YJ, Que JY, Yuan K, Deng JH, Teng T, Li YY, Sun W, Sun HQ, Vitiello MV, Tang XD, Zhou XY, Bao YP, Shi J, Lu L (2023) Efficacy and tolerability of pharmacological treatments for insomnia in adults: A systematic review and network meta-analysis. Sleep Med Rev 68:101746. https:\/\/doi.org\/10.1016\/j.smrv.2023.101746","journal-title":"Sleep Med Rev"},{"key":"4072_CR40","doi-asserted-by":"publisher","first-page":"1235","DOI":"10.1080\/14656566.2021.1902987","volume":"22","author":"G Zammit","year":"2021","unstructured":"Zammit G, Krystal A (2021) Evaluating lemborexant for the treatment of insomnia. Expert Opin Pharmacother 22:1235\u20131243. https:\/\/doi.org\/10.1080\/14656566.2021.1902987","journal-title":"Expert Opin Pharmacother"}],"container-title":["Naunyn-Schmiedeberg's Archives of Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00210-025-04072-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00210-025-04072-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00210-025-04072-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T04:10:57Z","timestamp":1759983057000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00210-025-04072-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,17]]},"references-count":40,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2025,10]]}},"alternative-id":["4072"],"URL":"https:\/\/doi.org\/10.1007\/s00210-025-04072-4","relation":{},"ISSN":["0028-1298","1432-1912"],"issn-type":[{"value":"0028-1298","type":"print"},{"value":"1432-1912","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,17]]},"assertion":[{"value":"14 November 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 March 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 April 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}